Please login to the form below

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed

Latest news

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... The trial studied Lartruvo combined with standard treatment doxorubicin,
EMA says Lilly’s Lartruvo should not be prescribed

Lilly said at the time it would stop promoting Lartruvo and would book a $70m-$90m charge this quarter as a result. ... Meanwhile, the trial failure also impacts Lartruvo in the US, as the FDA also approved the drug early on the promise of follow-up data.
Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients. The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of patients with advanced soft ... Until then, Lartruvo will be
Lilly snags first approval for sarcoma drug Lartruvo

Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending a four-decade drought for new front-line therapies. ... The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with
Lilly closes on first approval for sarcoma drug Lartruvo

Eli Lilly could be just weeks away from EU approval of its advanced soft tissue sarcoma (STS) treatment Lartruvo after a positive recommendation from the Committee for Medicinal Products for Human ... It is thought that by binding to the receptor

More from news
Approximately 6 fully matching, plus 0 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),